Physician profile
Keriann Gray
NPI 1023215670
$434.69
in general payments reported to CMS, 2019-2025
13 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.88 · 2023: $119 · 2024: $159 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.79 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $82.19 | 2023-2024 | Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $67.75 | 2024-2025 | |
| Daiichi Sankyo INC. | $54.77 | 2025 | Enhertu |
| Astellas Pharma US INC | $46.44 | 2024 | Vyloy, Xtandi |
| Celgene Corporation | $31.42 | 2023-2025 | Reblozyl |
| Abbvie INC. | $27.17 | 2024 | |
| Genzyme Corporation | $25.12 | 2024 | |
| Menarini Silicon Biosystems, INC. | $20.18 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $19.90 | 2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $15.85 | 2023 | Tazverik |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keriann Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.